Probiotics and gastrointestinal health - PubMed (original) (raw)
Probiotics and gastrointestinal health
S L Gorbach. Am J Gastroenterol. 2000 Jan.
Abstract
Evidence for positive health benefits of Lactobacilli applies to only a few strains used for commercial applications. It is generally agreed that a probiotic must be capable of colonizing the intestinal tract to influence human health; this requirement disqualifies many of the strains currently used in fermented dairy products. Lactobacillus GG, a variant of L. casei sps rhamnosus, has been studied extensively in adults and children. When consumed as a dairy product or as a lyophilized powder, LGG colonizes the gastrointestinal tract for 1-3 days in most individuals and up to 7 days in about 30% of subjects. Traveler's diarrhea, antibiotic-associated diarrhea, and relapsing Clostridium difficile colitis are improved with LGG. In infantile diarrhea, the severity and duration of the attack is reduced. LGG-fermented milk lessens the intestinal permeability defects caused by exposure to cows milk or rotavirus infection. LGG has proven beneficial effects on intestinal immunity. It increases the numbers of IgA and other immunoglobulin-secreting cells in the intestinal mucosa. LGG stimulates local release of interferon. It facilitates antigen transport to underlying lymphoid cells, which serves to increase antigen uptake in Peyer's patches. LGG also acts as an immunoadjuvant for oral vaccines. In an animal model of colon cancer, LGG reduced the incidence of chemically induced tumors in the large bowel of rodents. Extensive safety testing has shown no pathogenic potential in humans or animals. Probiotic cultures of Lactobacilli have the potential to bring substantial health benefits to the consumer. The purported benefits for any probiotic must pass the highest standards of scientific scrutiny before the claims can be accepted.
Similar articles
- Probiotics.
Gupta V, Garg R. Gupta V, et al. Indian J Med Microbiol. 2009 Jul-Sep;27(3):202-9. doi: 10.4103/0255-0857.53201. Indian J Med Microbiol. 2009. PMID: 19584499 Review. - Probiotics in digestive diseases: focus on Lactobacillus GG.
Pace F, Pace M, Quartarone G. Pace F, et al. Minerva Gastroenterol Dietol. 2015 Dec;61(4):273-92. Minerva Gastroenterol Dietol. 2015. PMID: 26657927 Review. - Protection from gastrointestinal diseases with the use of probiotics.
Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Marteau PR, et al. Am J Clin Nutr. 2001 Feb;73(2 Suppl):430S-436S. doi: 10.1093/ajcn/73.2.430s. Am J Clin Nutr. 2001. PMID: 11157353 Review. - Clinical indications for probiotics: an overview.
Goldin BR, Gorbach SL. Goldin BR, et al. Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S96-100; discussion S144-51. doi: 10.1086/523333. Clin Infect Dis. 2008. PMID: 18181732 Review. - Probiotic agents and infectious diseases: a modern perspective on a traditional therapy.
Alvarez-Olmos MI, Oberhelman RA. Alvarez-Olmos MI, et al. Clin Infect Dis. 2001 Jun 1;32(11):1567-76. doi: 10.1086/320518. Epub 2001 May 4. Clin Infect Dis. 2001. PMID: 11340528 Review.
Cited by
- Differential targeting of the E-Cadherin/β-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function.
Hummel S, Veltman K, Cichon C, Sonnenborn U, Schmidt MA. Hummel S, et al. Appl Environ Microbiol. 2012 Feb;78(4):1140-7. doi: 10.1128/AEM.06983-11. Epub 2011 Dec 16. Appl Environ Microbiol. 2012. PMID: 22179242 Free PMC article. - Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression.
Ma D, Forsythe P, Bienenstock J. Ma D, et al. Infect Immun. 2004 Sep;72(9):5308-14. doi: 10.1128/IAI.72.9.5308-5314.2004. Infect Immun. 2004. PMID: 15322027 Free PMC article. - Preliminary evaluation of Lactobacillus rhamnosus strain GG, a potential probiotic in dogs.
Weese JS, Anderson ME. Weese JS, et al. Can Vet J. 2002 Oct;43(10):771-4. Can Vet J. 2002. PMID: 12395758 Free PMC article. - Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment.
Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB. Dieleman LA, et al. Gut. 2003 Mar;52(3):370-6. doi: 10.1136/gut.52.3.370. Gut. 2003. PMID: 12584218 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous